Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.43 |
| ▸ | CCKAR | P32238 | 3/20 | 0.41 |
| ▸ | CCKBR | P32239 | 3/20 | 0.41 |
| ▸ | PLK1 | P53350 | 3/20 | 0.40 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834150 | 0.97 | HCAR2 (0.44) | HCAR2HDAC3HDAC1CCKARCCKBR | |
| SCHEMBL6834023 | 0.94 | HCAR2 (0.43) | HCAR2CCKARCCKBR | |
| SCHEMBL6833331 | 0.90 | PTPN2 (0.44) | HDAC3HDAC1PLK1PLK3 | |
| SCHEMBL6834575 | 0.89 | PTPN2 (0.46) | HDAC3HDAC1PLK1PLK3 | |
| SCHEMBL6834131 | 0.89 | PTPN2 (0.46) | HDAC3HDAC1PLK1PLK3 | |
| SCHEMBL6830691 | 0.89 | PLK1 (0.47) | HCAR2HDAC3HDAC1PLK1PLK3 | |
| SCHEMBL6835693 | 0.89 | POLB (0.47) | HDAC3HDAC1PLK1 | |
| SCHEMBL6834504 | 0.89 | LMNA (0.47) | CCKARCCKBR | |
| SCHEMBL6834088 | 0.87 | HDAC3 (0.46) | HCAR2HDAC3HDAC1 | |
| SCHEMBL6833910 | 0.87 | KDM4E (0.45) | HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | HCAR2 344/4885HDAC3 1562/4885HDAC1 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.